CRMD CorMedix Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%
Returns
ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $311.71M | $43.47M |
| Cost of revenue | $22.09M | $3.03M |
| Gross profit | $275.75M | $40.28M |
| R&D expense | $19.33M | $3.94M |
| SG&A expense | $68.22M | $29.96M |
| Operating income | $150.14M | -$22.36M |
| Interest expense | $2.78M | $36,000 |
| Pretax income | $150.02M | -$19.32M |
| Income tax | -$13.04M | -$1.40M |
| Net income | $163.06M | -$17.93M |
| EBITDA | $150.82M | -$22.20M |
| EPS (basic) | 2.25 | -0.30 |
| EPS (diluted) | 2.04 | -0.30 |
| Weighted avg. shares (diluted) | 80,308 | 58,872 |
| Banking | ||
| Net interest income | — | $1.40M |
| Balance sheet | ||
| Cash & equivalents | $144.84M | $40.76M |
| Short-term investments | $3.69M | $11.04M |
| Receivables | $171.23M | $51.65M |
| Inventory | $29.72M | $7.60M |
| Current assets | $367.05M | $114.58M |
| PP&E, net | $5.96M | $1.83M |
| Goodwill | $30.00M | — |
| Intangibles | $379.07M | $1.84M |
| Total assets | $826.14M | $118.85M |
| Current liabilities | $174.27M | $33.84M |
| Long-term debt | $150,000 | — |
| Total debt | $150,000 | — |
| Total liabilities | $420.83M | $34.19M |
| Shareholders' equity | $405.31M | $84.66M |
| Net debt | -$144.69M | — |
| Shares outstanding | 79.26M | 64.41M |
| Cash flow statement | ||
| Operating cash flow | $175.05M | -$50.62M |
| Capital expenditure | $2.26M | $116,000 |
| Free cash flow | $172.79M | -$50.73M |
| Investing cash flow | -$308.43M | $21.23M |
| Financing cash flow | $238.45M | $26.32M |
| Depreciation & amortization | $677,000 | $154,000 |
| Stock-based compensation | $13.83M | $6.13M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.